Monday, Oct 1, 2018
Genentech to Present Five-Year OCREVUS (Ocrelizumab) Efficacy and Safety Data in Relapsing and Primary Progressive Multiple Sclerosis at ECTRIMS
- Data reinforce importance of early initiation and continuation of OCREVUS treatment
- New analyses highlight the need for active treatment in underrepresented populations, such as primary progressive MS (PPMS) patients with more advanced disability and relapsing MS (RMS) patients of African-descent
- Genentech continues to advance the clinical understanding of MS with new studies incorporating novel clinical endpoints and digital tools
South San Francisco, CA -- October 1, 2018 --
No comments:
Post a Comment
Thank You for leaving a comment.
Attempts to redirect viewers of this blog to another website and / or any marketing, will be removed.
Note: Only a member of this blog may post a comment.